Ascentage Pharma Group International (AAPG) Competitors $25.03 +2.03 (+8.83%) As of 02:03 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock AAPG vs. ROIV, RVMD, BPMC, BBIO, ELAN, VRNA, TLX, LNTH, TGTX, and GRFSShould you be buying Ascentage Pharma Group International stock or one of its competitors? The main competitors of Ascentage Pharma Group International include Roivant Sciences (ROIV), Revolution Medicines (RVMD), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Verona Pharma (VRNA), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Lantheus (LNTH), TG Therapeutics (TGTX), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry. Ascentage Pharma Group International vs. Roivant Sciences Revolution Medicines Blueprint Medicines BridgeBio Pharma Elanco Animal Health Verona Pharma Telix Pharmaceuticals Limited American Depositary Shares Lantheus TG Therapeutics Grifols Roivant Sciences (NASDAQ:ROIV) and Ascentage Pharma Group International (NASDAQ:AAPG) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, community ranking, analyst recommendations, valuation, institutional ownership and dividends. Which has stronger earnings & valuation, ROIV or AAPG? Roivant Sciences has higher earnings, but lower revenue than Ascentage Pharma Group International. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoivant Sciences$122.59M64.20$4.35B-$0.15-73.53Ascentage Pharma Group International$980.65M2.23N/AN/AN/A Do analysts prefer ROIV or AAPG? Roivant Sciences currently has a consensus price target of $17.50, indicating a potential upside of 58.67%. Given Roivant Sciences' higher probable upside, analysts plainly believe Roivant Sciences is more favorable than Ascentage Pharma Group International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Ascentage Pharma Group International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer ROIV or AAPG? In the previous week, Roivant Sciences had 15 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 15 mentions for Roivant Sciences and 0 mentions for Ascentage Pharma Group International. Roivant Sciences' average media sentiment score of 1.44 beat Ascentage Pharma Group International's score of 0.00 indicating that Roivant Sciences is being referred to more favorably in the media. Company Overall Sentiment Roivant Sciences Positive Ascentage Pharma Group International Neutral Do insiders & institutionals believe in ROIV or AAPG? 64.8% of Roivant Sciences shares are owned by institutional investors. 7.9% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community believe in ROIV or AAPG? Roivant Sciences received 54 more outperform votes than Ascentage Pharma Group International when rated by MarketBeat users. However, 100.00% of users gave Ascentage Pharma Group International an outperform vote while only 78.57% of users gave Roivant Sciences an outperform vote. CompanyUnderperformOutperformRoivant SciencesOutperform Votes5578.57% Underperform Votes1521.43% Ascentage Pharma Group InternationalOutperform Votes1100.00% Underperform VotesNo Votes Is ROIV or AAPG more profitable? Ascentage Pharma Group International has a net margin of 0.00% compared to Roivant Sciences' net margin of -119.54%. Ascentage Pharma Group International's return on equity of 0.00% beat Roivant Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Roivant Sciences-119.54% -14.05% -12.81% Ascentage Pharma Group International N/A N/A N/A SummaryRoivant Sciences beats Ascentage Pharma Group International on 9 of the 14 factors compared between the two stocks. Get Ascentage Pharma Group International News Delivered to You Automatically Sign up to receive the latest news and ratings for AAPG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AAPG vs. The Competition Export to ExcelMetricAscentage Pharma Group InternationalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.18B$6.54B$5.40B$8.49BDividend YieldN/A2.66%5.22%4.11%P/E RatioN/A9.1826.7119.93Price / Sales2.23256.43395.44119.84Price / CashN/A65.8538.2534.62Price / BookN/A6.536.854.59Net IncomeN/A$144.00M$3.23B$248.19M7 Day Performance7.22%5.01%5.35%2.21%1 Month Performance31.22%9.58%13.31%16.23%1 Year PerformanceN/A-0.94%17.58%8.00% Ascentage Pharma Group International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AAPGAscentage Pharma Group InternationalN/A$25.03+8.8%N/AN/A$2.18B$980.65M0.00600Gap UpROIVRoivant Sciences2.0126 of 5 stars$10.79+0.3%$17.50+62.2%-2.9%$7.70B$122.59M-71.93860Positive NewsRVMDRevolution Medicines4.4108 of 5 stars$39.54+0.3%$67.08+69.7%+1.1%$7.37B$742,000.00-11.01250Positive NewsBPMCBlueprint Medicines2.6687 of 5 stars$101.69+2.2%$126.56+24.5%-1.2%$6.57B$562.12M-94.16640Positive NewsBBIOBridgeBio Pharma4.6353 of 5 stars$33.84+0.3%$57.09+68.7%+14.2%$6.43B$127.42M-11.87400Insider TradeELANElanco Animal Health3.2686 of 5 stars$12.940.0%$15.00+16.0%-23.1%$6.42B$4.43B32.349,800Analyst ForecastVRNAVerona Pharma1.8852 of 5 stars$71.31+2.6%$81.50+14.3%+484.7%$5.78B$118.54M-37.1430Positive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.68+2.6%$22.00+31.9%N/A$5.64B$783.21M0.00N/APositive NewsGap UpLNTHLantheus4.4894 of 5 stars$81.24+1.8%$132.67+63.3%-7.3%$5.62B$1.54B13.52700Positive NewsTGTXTG Therapeutics3.8221 of 5 stars$34.36+2.3%$40.80+18.7%+115.2%$5.46B$386.39M-343.57290Positive NewsGRFSGrifols3.1881 of 5 stars$7.76-1.1%N/A+4.7%$5.34B$7.21B6.6326,300 Related Companies and Tools Related Companies ROIV Alternatives RVMD Alternatives BPMC Alternatives BBIO Alternatives ELAN Alternatives VRNA Alternatives TLX Alternatives LNTH Alternatives TGTX Alternatives GRFS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AAPG) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascentage Pharma Group International Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascentage Pharma Group International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AAPG Stock Free AAPG Stock Alerts